DGIdb - VINBLASTINE Drug Record

VINBLASTINE chembl:CHEMBL159 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-47842
[3H]-VINBLASTINE
VELBAN
VINBLASTINE

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1965
FDA Approval	1965
Drug Class	small molecule
Drug Indications	Antineoplastic Agents

(3 More Sources)

Publications:

Zheng J et al., 2013, Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity., Eur J Med Chem
Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
Nievergelt A et al., 2010, Identification of serotonin 5-HT1A receptor partial agonists in ginger., Bioorg Med Chem
Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
Correia, 1991, Effects of antimitotic agents on tubulin-nucleotide interactions., Pharmacol. Ther.
Gupta et al., 2003, Antimicrotubular drugs binding to vinca domain of tubulin., Mol. Cell. Biochem.
Islam et al., 2004, Microtubulin binding sites as target for developing anticancer agents., Mini Rev Med Chem
Jordan et al., 2007, How do microtubule-targeted drugs work? An overview., Curr Cancer Drug Targets
Jordan et al., 1998, Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle., Med Res Rev
Vogelzang et al., 1982, Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors., Cancer Res.
Vacca et al., 1999, Antiangiogenesis is produced by nontoxic doses of vinblastine., Blood
Bornmann et al., 1994, Analysis of drug transport kinetics in multidrug-resistant cells using a novel coumarin-vinblastine compound., Biochemistry
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Aglietta et al., 2000, Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease., Cancer
Tishler et al., 1996, The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1., Br. J. Cancer Suppl.
Seidman et al., 1992, Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer., J. Urol.
Gröne et al., 1998, Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine., Exp. Toxicol. Pathol.
Sheridan et al., 1996, Microtubules regulate pulmonary vascular smooth muscle contraction., J. Surg. Res.
Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
Warberg et al., 1980, Ion-induced release of LHRH, TRH and alpha-MSH from hypothalamic synaptosomes and its inhibition by vinblastine., Pflugers Arch.

VINBLASTINE PTHLH

Interaction Score: 2.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9784008

Sources:
NCI
VINBLASTINE CGA

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6181870

Sources:
NCI
VINBLASTINE TRH

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6774314

Sources:
NCI
VINBLASTINE ABCB4

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7918493

Sources:
NCI
VINBLASTINE TBXA2R

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8632653

Sources:
NCI
VINBLASTINE TUBA1A

Interaction Score: 0.39

Interaction Types & Directionality:

adduct

Interaction Info:

PMIDs:
23708010 23916255 1818332 14619954 15579115 18220533 9664292

Sources:
DTC
VINBLASTINE TUBB

Interaction Score: 0.32

Interaction Types & Directionality:

adduct

inhibitor (inhibitory)

Interaction Info:

PMIDs:
23708010 23916255 1818332 14619954 15579115 18220533 9664292

Sources:
DTC
VINBLASTINE TUBB4A

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA3C

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB2A

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
23708010 23916255

Sources:
DTC TdgClinicalTrial TEND
VINBLASTINE KLK3

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1371564

Sources:
NCI
VINBLASTINE CDKN1A

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8763853

Sources:
NCI
VINBLASTINE GSTM1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23323945

Sources:
PharmGKB
VINBLASTINE TUBB4B

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC TTD
VINBLASTINE MMP2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10590059

Sources:
NCI
VINBLASTINE TUBB8

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA3E

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA1B

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA4A

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB2B

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB6

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA3D

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA1C

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB3

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE CSF2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10640980

Sources:
NCI
VINBLASTINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20363635 21348461

Sources:
DTC
VINBLASTINE NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINBLASTINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528

Sources:
PharmGKB
VINBLASTINE GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: VINBLASTINE
- Version: 01-August-2011
Alternate Names:

VINBLASTINE Primary Drug Name

Drug Info:

Year of Approval 1965

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: VINBLASTINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1965

Publications:

NCI: VINBLASTINE

Version: 14-September-2017

Alternate Names:

C930 NCI drug code

Drug Info:

Publications:

Bornmann et al., 1994, Analysis of drug transport kinetics in multidrug-resistant cells using a novel coumarin-vinblastine compound., Biochemistry

Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.

Gröne et al., 1998, Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine., Exp. Toxicol. Pathol.

DTC: VINBLASTINE

Version: 02-September-2020

Alternate Names:

CHEMBL159 ChEMBL Drug ID

Drug Info:

Publications:

Zheng J et al., 2013, Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity., Eur J Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod

PharmGKB: vinblastine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma

TTD: Vinblastine
- Version: 2020.06.01
Alternate Names:

D0W9MM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL159
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

adduct
inhibitor (inhibitory)

Novel drug target	Established target
Trial Name	-

VINBLASTINE Drug Record

VINBLASTINE chembl:CHEMBL159 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9784008

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6181870

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6774314

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7918493

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8632653

Sources: NCI

Interaction Types & Directionality: adduct

Interaction Info:

PMIDs: 23708010 23916255 1818332 14619954 15579115 18220533 9664292

Sources: DTC

Interaction Types & Directionality: adduct inhibitor (inhibitory)

Interaction Info:

PMIDs: 23708010 23916255 1818332 14619954 15579115 18220533 9664292

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 23708010 23916255

Sources: DTC TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1371564

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8763853

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23323945

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10590059

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Interaction Types & Directionality:

n/a

PMIDs:
9784008

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6181870

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6774314

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7918493

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8632653

Sources:
NCI

Interaction Types & Directionality:

adduct

PMIDs:
23708010 23916255 1818332 14619954 15579115 18220533 9664292

Sources:
DTC

Interaction Types & Directionality:

adduct

inhibitor (inhibitory)

PMIDs:
23708010 23916255 1818332 14619954 15579115 18220533 9664292

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
23708010 23916255

Sources:
DTC TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
1371564

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8763853

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23323945

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC TTD

Interaction Types & Directionality:

n/a

PMIDs:
10590059

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
10640980

Sources:
NCI

Interaction Types & Directionality:

n/a